Miraa (Khat) Use Disorder: Neurobiology, Health Risks, and Evidence-Based Management of Stimulant Dependence

Miraa, also known as khat (Catha edulis), is a plant whose leaves are traditionally chewed for stimulant effects. The primary psychoactive constituent is cathinone (and, in fresh material, higher-cathinone content than in aged leaves), which acts as a central nervous system stimulant. Cathinone increases synaptic monoamines—especially dopamine and norepinephrine—by promoting release and inhibiting reuptake, producing a subjective state of alertness, talkativeness, and reduced perceived fatigue. Despite cultural contexts, miraa use can evolve into maladaptive patterns consistent with stimulant use disorder, with clinically meaningful impairment in social functioning, occupational performance, and physical health.

Epidemiology and patterning of use vary by region and community. However, chronic use is associated with tolerance and dependence-like phenomena. Tolerance may emerge because repeated dopaminergic stimulation leads to compensatory downregulation of reward pathways and altered receptor signaling. Dependence is supported by withdrawal symptoms when use is reduced or stopped, such as irritability, dysphoria, anxiety, restlessness, disturbed sleep, decreased appetite, and cravings. Some individuals also experience difficulty concentrating and low motivation during abstinence, reflecting neuroadaptations in prefrontal-limbic circuitry.

Physiologically, miraa’s sympathomimetic effects can raise heart rate and blood pressure. Acute use may precipitate palpitations and exacerbate preexisting cardiovascular disease. Over time, repeated stimulant exposure can worsen metabolic parameters, including glucose regulation and lipid profiles, particularly in individuals with co-occurring risk factors. Gastrointestinal effects are also reported: nausea, anorexia, and weight changes, alongside oral complications from chewing. Oral mucosal irritation, gingival disease, dental staining, and chronic ulcerations have been described, partly due to local chemical irritation and mechanical trauma from prolonged chewing.

Neuropsychiatric consequences include anxiety and sleep disruption. Users may perceive short-term anxiety relief due to heightened arousal and distraction, but rebound anxiety can occur as stimulant levels wane. Psychosis-like symptoms—paranoia, hallucinations, disorganized thinking—have been described in heavy or vulnerable individuals, likely related to excessive dopaminergic activity in mesolimbic pathways. Mood symptoms can also intensify: agitation, depressive episodes during withdrawal, and emotional dysregulation when stimulant intake is interrupted.

From a diagnostic perspective, the clinical picture resembles other stimulant-related disorders. DSM-oriented frameworks emphasize a cluster of impaired control, social/occupational impairment, risky use, tolerance, and withdrawal. Assessment should consider quantity, frequency, route (chewing vs. other forms), duration of heavy use, comorbid psychiatric illness (e.g., anxiety disorders, major depression, attention-deficit/hyperactivity disorder), and medical comorbidities (hypertension, arrhythmia risk, dental disease). Because social stigma can obscure symptom reporting, clinicians should use nonjudgmental, structured interviews and standardized screening tools when available.

Evidence-based management prioritizes harm reduction and, when appropriate, structured treatment for stimulant use disorder. Psychosocial interventions are central. Motivational interviewing can improve readiness to change by exploring ambivalence and linking use to personal goals. Cognitive behavioral therapy (CBT) can target cue-triggered cravings, coping strategies, and cognitive distortions that perpetuate use. Contingency management—reinforcing abstinence or attendance with tangible incentives—has strong evidence for stimulant addictions in general and may be adapted to miraa contexts.

Pharmacotherapy is not uniformly established specifically for khat, but clinicians may treat co-occurring conditions: for example, insomnia may be managed with sleep hygiene and, when needed, short-term targeted approaches; anxiety and depressive symptoms may warrant antidepressant or anxiolytic strategies based on clinical judgment and diagnostic clarity. Importantly, benzodiazepines should be used cautiously because of sedation, dependence risk, and limited evidence in this specific context. During withdrawal, monitoring for severe agitation, suicidal ideation, dehydration, or medical instability is crucial.

Relapse prevention requires identifying triggers—social settings, stress, and habitual chewing routines—and building alternative reward pathways through behavioral activation, structured daily schedules, and support networks. Family-based interventions can improve adherence and reduce conflict. Long-term recovery outcomes are influenced by the severity and duration of use, baseline mental health, and the stability of the patient’s psychosocial environment.

Public health considerations include education about stimulant risks, oral health screening, cardiovascular risk assessment, and integration of substance-use care into primary healthcare. Clinicians should approach miraa use with cultural sensitivity while emphasizing that neurobiological stimulant mechanisms can lead to dependence, withdrawal syndromes, and significant medical and psychiatric morbidity.

Source: [Creator] @Jaeamii (Source Link: https://x.com/Jaeamii/status/2068450107796689337)